Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 15/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 15/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 14/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 14/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 12/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26334441 | 1.00 | HTR2C (0.46) | HTR2CCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL2379324 | 1.00 | HTR2C (0.46) | HTR2CCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL6367254 | 1.00 | HTR2C (0.46) | HTR2CCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL28949604 | 1.00 | HTR2C (0.46) | HTR2CCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL2846979 | 1.00 | HTR2C (0.46) | HTR2CCHRNB2CHRNA4CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL21816672 | 0.98 | HTR2C (0.45) | HTR2CCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL377976 | 0.80 | CHRNB2 (0.46) | HTR2CCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL18081172 | 0.80 | CHRNB2 (0.46) | HTR2CCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1481267 | 0.80 | CHRNB2 (0.46) | HTR2CCHRNB2CHRNA4CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL15956717 | 0.78 | CHRNB2 (0.45) | HTR2CCHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080096-A1 | Condensed heterocyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080096-A1 | Condensed heterocyclic compounds | PARP1, PARP2, PARP3 | HTR2C 543/4885CHRNB2 3903/4885CHRNA4 3387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.